Daiichi Sankyo announced that it has administered an mRNA vaccine (DS-5670) against the novel coronavirus infectious disease (Covid-19), which is being developed by Daiichi Sankyo in Japan, to the first subject in a phase 3 clinical trial of a booster vaccination with an Omicron-adapted bivalent vaccine (booster vaccination trial).
This booster vaccination trial is a phase 3 clinical trial that enrolls approximately 1,400 healthy individuals who have completed the primary and booster series of vaccination with a Covid-19 vaccine approved in Japan and evaluates the efficacy and safety of DS-5670 (Omicron-adapted bivalent vaccine) using a Covid19 vaccine (Omicron-adapted bivalent vaccine) approved in Japan as the control.
Based on results from the booster vaccination trial, Daiichi Sankyo will pursue the approval of the Omicron adapted bivalent vaccine. Furthermore, the company will continuously work toward supplying mRNA vaccines
against new variants of coronavirus.
DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by Daiichi Sankyo. It is designed to produce antibodies against the receptor binding domain (RBD) of the spike protein of the novel coronavirus and thus expected to have desirable prevention against Covid-19 and safety.
Daiichi Sankyo aims to make it possible to distribute the mRNA vaccine at refrigeration temperatures (2-8?).
The clinical development of DS-5670, including the mutant strain vaccine announced today, is being conducted through the
